APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal Bacteria Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pneumococcal Bacteria Vaccine Market Outlook and Growth Opportunities 2026

2 January 2026194 pages

Choose your research edition.

Industry ResearchPneumococcal Bacteria Vaccine Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal Bacteria Vaccine Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Pneumococcal Bacteria Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal Bacteria Vaccine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal Bacteria Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Pneumococcal Bacteria Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pneumococcal Bacteria Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumococcal Bacteria Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumococcal Bacteria Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pneumococcal Bacteria Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pneumococcal Bacteria Vaccine market include Sanofi, Merck, Pfizer, GSK, Walvax and Sinopharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pneumococcal Bacteria Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumococcal Bacteria Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumococcal Bacteria Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumococcal Bacteria Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumococcal Bacteria Vaccine Segment by Company

Sanofi

Merck

Pfizer

GSK

Walvax

Sinopharm

Pneumococcal Bacteria Vaccine Segment by Type

PPSV 23

PCV 13

PCV 10

Pneumococcal Bacteria Vaccine Segment by Application

Infant

Children

Adult

Pneumococcal Bacteria Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pneumococcal Bacteria Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pneumococcal Bacteria Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pneumococcal Bacteria Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Pneumococcal Bacteria Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Bacteria Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Bacteria Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Bacteria Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumococcal Bacteria Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pneumococcal Bacteria Vaccine industry.

Chapter 3: Detailed analysis of Pneumococcal Bacteria Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pneumococcal Bacteria Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pneumococcal Bacteria Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pneumococcal Bacteria Vaccine Industry Trends Table 2. Pneumococcal Bacteria Vaccine Industry Drivers Table 3. Pneumococcal Bacteria Vaccine Industry Opportunities and Challenges Table 4. Pneumococcal Bacteria Vaccine Industry Restraints Table 5. Global Pneumococcal Bacteria Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pneumococcal Bacteria Vaccine Revenue Share by Company (2021-2026) Table 7. Global Pneumococcal Bacteria Vaccine Sales Volume by Company (K Doses) & (2021-2026) Table 8. Global Pneumococcal Bacteria Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Pneumococcal Bacteria Vaccine Average Price (US$/Dose) of Company (2021-2026) Table 10. Global Pneumococcal Bacteria Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pneumococcal Bacteria Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Pneumococcal Bacteria Vaccine Company, Product Type & Application Table 13. Global Pneumococcal Bacteria Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumococcal Bacteria Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PPSV 23 Table 18. Significant Companies of PCV 13 Table 19. Significant Companies of PCV 10 Table 20. Global Pneumococcal Bacteria Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Doses) Table 21. Global Pneumococcal Bacteria Vaccine Sales Volume by Type (2021-2026) & (K Doses) Table 22. Global Pneumococcal Bacteria Vaccine Sales Volume by Type (2027-2032) & (K Doses) Table 23. Global Pneumococcal Bacteria Vaccine Sales Volume Share by Type (2021-2026) Table 24. Global Pneumococcal Bacteria Vaccine Sales Volume Share by Type (2027-2032) Table 25. Global Pneumococcal Bacteria Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pneumococcal Bacteria Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Pneumococcal Bacteria Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Pneumococcal Bacteria Vaccine Sales Value Share by Type (2021-2026) Table 29. Global Pneumococcal Bacteria Vaccine Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Infant Table 31. Significant Companies of Children Table 32. Significant Companies of Adult Table 33. Global Pneumococcal Bacteria Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Doses) Table 34. Global Pneumococcal Bacteria Vaccine Sales Volume by Application (2021-2026) & (K Doses) Table 35. Global Pneumococcal Bacteria Vaccine Sales Volume by Application (2027-2032) & (K Doses) Table 36. Global Pneumococcal Bacteria Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global Pneumococcal Bacteria Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global Pneumococcal Bacteria Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Pneumococcal Bacteria Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Pneumococcal Bacteria Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Pneumococcal Bacteria Vaccine Sales Value Share by Application (2021-2026) Table 42. Global Pneumococcal Bacteria Vaccine Sales Value Share by Application (2027-2032) Table 43. Global Pneumococcal Bacteria Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 44. Global Pneumococcal Bacteria Vaccine Sales by Region (2021-2026) & (K Doses) Table 45. Global Pneumococcal Bacteria Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Pneumococcal Bacteria Vaccine Sales by Region (2027-2032) & (K Doses) Table 47. Global Pneumococcal Bacteria Vaccine Sales Market Share by Region (2027-2032) Table 48. Global Pneumococcal Bacteria Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Pneumococcal Bacteria Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Pneumococcal Bacteria Vaccine Sales Value Share by Region (2021-2026) Table 51. Global Pneumococcal Bacteria Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Pneumococcal Bacteria Vaccine Sales Value Share by Region (2027-2032) Table 53. Global Pneumococcal Bacteria Vaccine Market Average Price (US$/Dose) by Region (2021-2026) Table 54. Global Pneumococcal Bacteria Vaccine Market Average Price (US$/Dose) by Region (2027-2032) Table 55. Global Pneumococcal Bacteria Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Table 56. Global Pneumococcal Bacteria Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Pneumococcal Bacteria Vaccine Sales by Country (2021-2026) & (K Doses) Table 58. Global Pneumococcal Bacteria Vaccine Sales Market Share by Country (2021-2026) Table 59. Global Pneumococcal Bacteria Vaccine Sales by Country (2027-2032) & (K Doses) Table 60. Global Pneumococcal Bacteria Vaccine Sales Market Share by Country (2027-2032) Table 61. Global Pneumococcal Bacteria Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Pneumococcal Bacteria Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global Pneumococcal Bacteria Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Pneumococcal Bacteria Vaccine Sales Value Market Share by Country (2027-2032) Table 65. Sanofi Company Information Table 66. Sanofi Business Overview Table 67. Sanofi Pneumococcal Bacteria Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 68. Sanofi Pneumococcal Bacteria Vaccine Product Portfolio Table 69. Sanofi Recent Development Table 70. Merck Company Information Table 71. Merck Business Overview Table 72. Merck Pneumococcal Bacteria Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 73. Merck Pneumococcal Bacteria Vaccine Product Portfolio Table 74. Merck Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Pneumococcal Bacteria Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 78. Pfizer Pneumococcal Bacteria Vaccine Product Portfolio Table 79. Pfizer Recent Development Table 80. GSK Company Information Table 81. GSK Business Overview Table 82. GSK Pneumococcal Bacteria Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 83. GSK Pneumococcal Bacteria Vaccine Product Portfolio Table 84. GSK Recent Development Table 85. Walvax Company Information Table 86. Walvax Business Overview Table 87. Walvax Pneumococcal Bacteria Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 88. Walvax Pneumococcal Bacteria Vaccine Product Portfolio Table 89. Walvax Recent Development Table 90. Sinopharm Company Information Table 91. Sinopharm Business Overview Table 92. Sinopharm Pneumococcal Bacteria Vaccine Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 93. Sinopharm Pneumococcal Bacteria Vaccine Product Portfolio Table 94. Sinopharm Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Pneumococcal Bacteria Vaccine Distributors List Table 98. Pneumococcal Bacteria Vaccine Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Pneumococcal Bacteria Vaccine Product Image Figure 2. Global Pneumococcal Bacteria Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal Bacteria Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pneumococcal Bacteria Vaccine Sales (2021-2032) & (K Doses) Figure 5. Global Pneumococcal Bacteria Vaccine Sales Average Price (US$/Dose) & (2021-2032) Figure 6. Global Pneumococcal Bacteria Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PPSV 23 Image Figure 10. PCV 13 Image Figure 11. PCV 10 Image Figure 12. Global Pneumococcal Bacteria Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 13. Global Pneumococcal Bacteria Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Pneumococcal Bacteria Vaccine Sales Volume Share by Type (2021-2032) Figure 15. Global Pneumococcal Bacteria Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Pneumococcal Bacteria Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Pneumococcal Bacteria Vaccine Sales Value Share by Type (2021-2032) Figure 18. Infant Image Figure 19. Children Image Figure 20. Adult Image Figure 21. Global Pneumococcal Bacteria Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 22. Global Pneumococcal Bacteria Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Pneumococcal Bacteria Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global Pneumococcal Bacteria Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Pneumococcal Bacteria Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Pneumococcal Bacteria Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global Pneumococcal Bacteria Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Figure 28. Global Pneumococcal Bacteria Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Pneumococcal Bacteria Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Pneumococcal Bacteria Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Pneumococcal Bacteria Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Pneumococcal Bacteria Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Pneumococcal Bacteria Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Pneumococcal Bacteria Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Pneumococcal Bacteria Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Pneumococcal Bacteria Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Pneumococcal Bacteria Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Pneumococcal Bacteria Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Pneumococcal Bacteria Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Pneumococcal Bacteria Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Pneumococcal Bacteria Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Pneumococcal Bacteria Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • PPSV 23
  • PCV 13
  • PCV 10
Applications
  • Infant
  • Children
  • Adult
Companies covered
  • Sanofi
  • Merck
  • Pfizer
  • GSK
  • Walvax
  • Sinopharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pneumococcal Bacteria Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Pneumococcal Bacteria Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Pneumococcal Bacteria Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pneumococcal Bacteria Vaccine Market Dynamics
  1. 2.1 Pneumococcal Bacteria Vaccine Industry Trends
  2. 2.2 Pneumococcal Bacteria Vaccine Industry Drivers
  3. 2.3 Pneumococcal Bacteria Vaccine Industry Opportunities and Challenges
  4. 2.4 Pneumococcal Bacteria Vaccine Industry Restraints
3 Pneumococcal Bacteria Vaccine Market by Company
  1. 3.1 Global Pneumococcal Bacteria Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Pneumococcal Bacteria Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Pneumococcal Bacteria Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Pneumococcal Bacteria Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Pneumococcal Bacteria Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Pneumococcal Bacteria Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Pneumococcal Bacteria Vaccine Company Product Type and Application
  8. 3.8 Global Pneumococcal Bacteria Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pneumococcal Bacteria Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pneumococcal Bacteria Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pneumococcal Bacteria Vaccine Market by Type
  1. 4.1 Pneumococcal Bacteria Vaccine Type Introduction
  2. 4.1.1 PPSV 23
  3. 4.1.2 PCV 13
  4. 4.1.3 PCV 10
  5. 4.2 Global Pneumococcal Bacteria Vaccine Sales Volume by Type
  6. 4.2.1 Global Pneumococcal Bacteria Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pneumococcal Bacteria Vaccine Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Pneumococcal Bacteria Vaccine Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Pneumococcal Bacteria Vaccine Sales Value by Type
  10. 4.3.1 Global Pneumococcal Bacteria Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pneumococcal Bacteria Vaccine Sales Value by Type (2021-2032)
  12. 4.3.3 Global Pneumococcal Bacteria Vaccine Sales Value Share by Type (2021-2032)
5 Pneumococcal Bacteria Vaccine Market by Application
  1. 5.1 Pneumococcal Bacteria Vaccine Application Introduction
  2. 5.1.1 Infant
  3. 5.1.2 Children
  4. 5.1.3 Adult
  5. 5.2 Global Pneumococcal Bacteria Vaccine Sales Volume by Application
  6. 5.2.1 Global Pneumococcal Bacteria Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pneumococcal Bacteria Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pneumococcal Bacteria Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pneumococcal Bacteria Vaccine Sales Value by Application
  10. 5.3.1 Global Pneumococcal Bacteria Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pneumococcal Bacteria Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pneumococcal Bacteria Vaccine Sales Value Share by Application (2021-2032)
6 Pneumococcal Bacteria Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Pneumococcal Bacteria Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumococcal Bacteria Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumococcal Bacteria Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Pneumococcal Bacteria Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Pneumococcal Bacteria Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pneumococcal Bacteria Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pneumococcal Bacteria Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pneumococcal Bacteria Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Pneumococcal Bacteria Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pneumococcal Bacteria Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Pneumococcal Bacteria Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pneumococcal Bacteria Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Pneumococcal Bacteria Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pneumococcal Bacteria Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pneumococcal Bacteria Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pneumococcal Bacteria Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Pneumococcal Bacteria Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pneumococcal Bacteria Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pneumococcal Bacteria Vaccine Sales Value Share by Country, 2025 VS 2032
7 Pneumococcal Bacteria Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Pneumococcal Bacteria Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pneumococcal Bacteria Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pneumococcal Bacteria Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Pneumococcal Bacteria Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Pneumococcal Bacteria Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Pneumococcal Bacteria Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pneumococcal Bacteria Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pneumococcal Bacteria Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pneumococcal Bacteria Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pneumococcal Bacteria Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pneumococcal Bacteria Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Pneumococcal Bacteria Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Pneumococcal Bacteria Vaccine Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Pneumococcal Bacteria Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Pneumococcal Bacteria Vaccine Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Pneumococcal Bacteria Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Pneumococcal Bacteria Vaccine Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Pneumococcal Bacteria Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GSK Pneumococcal Bacteria Vaccine Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Walvax
  26. 8.5.1 Walvax Company Information
  27. 8.5.2 Walvax Business Overview
  28. 8.5.3 Walvax Pneumococcal Bacteria Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Walvax Pneumococcal Bacteria Vaccine Product Portfolio
  30. 8.5.5 Walvax Recent Developments
  31. 8.6 Sinopharm
  32. 8.6.1 Sinopharm Company Information
  33. 8.6.2 Sinopharm Business Overview
  34. 8.6.3 Sinopharm Pneumococcal Bacteria Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sinopharm Pneumococcal Bacteria Vaccine Product Portfolio
  36. 8.6.5 Sinopharm Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumococcal Bacteria Vaccine Value Chain Analysis
  2. 9.1.1 Pneumococcal Bacteria Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumococcal Bacteria Vaccine Sales Mode & Process
  6. 9.2 Pneumococcal Bacteria Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumococcal Bacteria Vaccine Distributors
  9. 9.2.3 Pneumococcal Bacteria Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst